

ChemoCentryx, Inc.
Form 3
February 08, 2012

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

<p>1. Name and Address of Reporting Person *</p> <p>TECHNE CORP /MN/</p> <p>(Last) (First) (Middle)</p> <p>614 MCKINLEY PLACE NE</p> <p>(Street)</p> <p>MINNEAPOLIS, MN 55413</p> <p>(City) (State) (Zip)</p>	<p>2. Date of Event Requiring Statement</p> <p>(Month/Day/Year)</p> <p>02/08/2012</p>	<p>3. Issuer Name and Ticker or Trading Symbol</p> <p>ChemoCentryx, Inc. [CCXI]</p>	<p>4. Relationship of Reporting Person(s) to Issuer</p> <p>(Check all applicable)</p> <p><input type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input type="checkbox"/> Officer <input type="checkbox"/> Other (give title below) (specify below)</p>	<p>5. If Amendment, Date Original Filed(Month/Day/Year)</p>	<p>6. Individual or Joint/Group Filing(Check Applicable Line)</p> <p><input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person</p>
---	---	---	---	---	---

Table I - Non-Derivative Securities Beneficially Owned

<p>1. Title of Security (Instr. 4)</p>	<p>2. Amount of Securities Beneficially Owned (Instr. 4)</p>	<p>3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)</p>	<p>4. Nature of Indirect Beneficial Ownership (Instr. 5)</p>
--	--	---	--

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

<p>1. Title of Derivative Security (Instr. 4)</p>	<p>2. Date Exercisable and Expiration Date (Month/Day/Year)</p> <p>Date Exercisable Expiration Date</p>	<p>3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)</p> <p>Title Amount or Number of Shares</p>	<p>4. Conversion or Exercise Price of Derivative Security</p>	<p>5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)</p>	<p>6. Nature of Indirect Beneficial Ownership (Instr. 5)</p>
---	--	---	---	--	--

Edgar Filing: ChemoCentryx, Inc. - Form 3

Series A Preferred Stock	Â (1)	Â (1)	Common Stock	2,500,000	\$ (1)	D	Â
Series B Preferred Stock	Â (1)	Â (1)	Common Stock	973,418	\$ (1)	D	Â
Series C Preferred Stock	Â (1)	Â (1)	Common Stock	611,574	\$ (1)	D	Â
Series D Preferred Stock	Â (1)	Â (1)	Common Stock	628,574	\$ (1)	D	Â
Convertible Promissory Note	Â (2)	Â (2)	Common Stock	1,021,490 (3)	\$ (2)	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
TECHNE CORP /MN/ 614 MCKINLEY PLACE NE MINNEAPOLIS, MN 55413	Â	Â X	Â	Â

Signatures

Thomas E.
Oland, CEO

02/08/2012

**Signature of
Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The Issuer's Preferred Stock has no expiration date, is convertible at any time, in whole or in part, at the election of the holder, and will

(1) automatically convert upon the closing of the Issuer's initial public offering (the "IPO") at a conversion ratio of one share of Common Stock for every two shares of Preferred Stock, rounded down to the next whole number, for no additional consideration.

The principal amount of the Convertible Promissory Note, plus accrued interest thereon, will automatically convert into shares of

(2) Common Stock upon the closing of the IPO at a conversion price of \$10.00 per share, the per share amount of the Common Stock being sold in the IPO.

(3) Assumes the IPO closing will occur on or about February 13, 2012.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.